A Review of Immune-Mediated Adverse Events in Melanoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Checkpoint inhibitor immunotherapy has revolutionized cancer treatment, particularly for melanoma.
• These therapies enhance anti-tumor immune responses, leading to long-term disease control.
• Immune system activation by these agents can cause distinct side effects known as immune-mediated adverse events (irAEs).

Purpose of the Study:

• To review immune-mediated adverse events (irAEs) associated with checkpoint inhibitors.
• To provide management guidelines for irAEs linked to PD-1 and CTLA-4 inhibitors.

Main Methods:

• Literature review focusing on clinical data and management strategies for irAEs.
• Analysis of side effect profiles for programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors.

Main Results:

• Checkpoint inhibitors can induce a range of irAEs affecting various organ systems.
• Early recognition and appropriate management are crucial for mitigating irAE severity and toxicity.
• Guidelines for managing irAEs are essential for safe and effective immunotherapy use.

Conclusions:

• Immune-mediated adverse events (irAEs) are a significant consideration in checkpoint inhibitor therapy.
• Effective management strategies are vital for optimizing patient outcomes and tolerability of PD-1 and CTLA-4 inhibitors.